



Research Article

Does the Nitric Oxide Synthase T786C Gene Polymorphism Influence Arterial Stiffness in Patients with Metabolic Syndrome?

Angela Cozma^{1,†}, Adriana Fodor^{2,†}, Lucia Maria Procopciuc³, Teodora Alexescu¹, Vasile Negrean¹, Dana Pop⁴, Doina Alina Todea⁵, Olga Hilda Orășan^{1,*}, Adela-Viviana Sitar-Taut¹

¹Internal Medicine Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

²Clinical Center of Diabetes, Nutrition, Metabolic diseases, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

³Department of Medical Biochemistry, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

⁴Department of Cardiology, Clinical Rehabilitation Hospital, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

⁵Department of Pneumology, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

ARTICLE INFO

Article History

Received 15 March 2019

Accepted 24 March 2020

Keywords

eNOS gene polymorphisms

T786C

arterial stiffness

metabolic syndrome

ABSTRACT

Background: Endothelial Nitric Oxide Synthase (eNOS) is responsible for Nitric Oxide (NO) bioavailability at endothelial level. Aging (even in healthy people) is involved in arterial stiffness increases.

Materials and Methods: We investigated (in the service of Cardiology, 4th Medical Clinic) 100 patients, 55 with metabolic syndrome (MS), mean age 56.91 ± 14.39 years, 66% women. Identification of the T786C polymorphism was performed by enzymatic digestion of the fragment obtained by polymerase chain reaction (PCR) amplification. Evaluation of arterial parameters (aortic pulse wave velocity (PWV), as a measure of arterial stiffness and aortic [AixAo] and brachial [Aixb] augmentation index) was performed with the TensioMed[®] Arteriograph.

Results: Regarding T786C polymorphism, the distribution was the following: 57% did not have the mutation (TT), 30% were heterozygous, 13% were homozygous (CC). Patients with MS more frequently had C allele (54.5% vs. 28.9% in those without MS) and CC state (16.4% vs. 8.9%, p -NS). Significant differences ($p = 0.005$) regarding PWV were found in TT patients vs. heterozygous CT vs. homozygous CC: 9.75 ± 1.75 m/s vs. 9.86 ± 1.56 m/s vs. 11.65 ± 1.87 m/s. In case of the other parameters, no significant differences were found (AixAo, $p = 0.35$; Aixb, $p = 0.22$; pulse pressure, $p = 0.14$), but CC patients presented higher values.

Conclusion: Arterial stiffness is influenced by eNOS gene polymorphisms, being a possible link between the increase in cardiovascular risk and presence of metabolic syndrome in these patients.

© 2020 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V. This is an open access article distributed under the CC BY-NC 4.0 license (<http://creativecommons.org/licenses/by-nc/4.0/>).

1. INTRODUCTION

An enzyme constitutively expressed mainly in endothelial cells, Endothelial Nitric Oxide Synthase (eNOS or NOS3), is responsible for Nitric Oxide (NO) bioavailability at endothelial level. Alterations in endothelial-derived NO production occurs in various cardiovascular diseases (coronary artery disease, myocardial infarction, hypertension, pre-eclampsia, stroke, metabolic syndrome and diabetes [1–11], associated with different polymorphisms in the eNOS gene – one of the most studied being represented by – 786T/C (rs2070744) [1–11]. Even in relatively

healthy people who are at low risk for cardiovascular disease, arterial stiffness increases with advancing age [12].

The interest in studying factors that modulate arterial stiffness is based on the relationship between arterial stiffness and pathogenesis of cardiovascular disease. A cluster entity characterized by hypertension, hyperglycemia, obesity, dyslipidemia, and insulin resistance is known as Metabolic Syndrome (MS). Atherosclerotic lesions in metabolic syndrome can be the result of endothelial dysfunction determined by alteration of nitric oxide production. NO has vasodilatory, antiproliferative and anti-inflammatory effects [13].

2. OBJECTIVES OF THE STUDY

In this study, we aimed to investigate the impact of eNOS T786C gene polymorphism on arterial stiffness, by measuring in patients with metabolic syndrome, arterial stiffness parameters -PWV and the augmentation index.

*Corresponding author. Email: olgaorasan@yahoo.com

[†]These authors contributed equally to this work.

Peer review under responsibility of the Association for Research into Arterial Structure and Physiology

Data availability statement: The data that support the findings of this study are available from the corresponding author (OHO), upon reasonable request.

3. MATERIALS AND METHODS

3.1. Subjects

One hundred consecutive patients were included in the study, who were investigated in the service of Cardiology, 4th Medical Clinic, University of Cluj-Napoca. Based on International Diabetes Federation (IDF) criteria, 55% of patients were diagnosed with metabolic syndrome (obligatory presence abdominal obesity ≥ 94 cm in men and ≥ 80 cm in women), and another two criteria for blood pressure above 130/85 mmHg, low High-density Lipoprotein (HDL)-cholesterol, glycemia ≥ 100 mg/dl and triglycerides ≥ 150 mg/dl).

Anthropometric measurements were performed and included weight, height and waist circumference. Based on anthropometric measurements, the body mass index was calculated. Blood pressure measurements were performed at least twice, in a quiet room after lying down for 15 min (according to present guidelines) in order to diagnose hypertension.

WHO criteria were used for type 2 diabetes' diagnosis. The levels of Triglycerides (TG), total cholesterol, Low-density Lipoproteins (LDL) and HDLs were estimated according to standard protocols.

The study protocol was approved by the local Ethics Committee, and all subjects provided an oral and written informed consent. The study was conducted in compliance with the Declaration of Helsinki.

3.2. DNA Isolation

The *T786C* polymorphism located in the *eNOS* gene promoter (chr 7q36) was examined by polymerase chain reaction (PCR) amplification of genomic DNA and enzymatic digestion with the restriction endonuclease of the amplified fragment polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP technique).

For the identification of the above mentioned polymorphism, DNA analysis according to the modified method described by Negrao was performed. Amplification was performed in 25 μ l reaction mixture, with the following reaction components: 20 ng genomic DNA, 0.2 mM dNTP, 0.2 μ M forward and reverse primer [(the forward primer had the sequence: 5'-TGG AGA GTG CTG GTG TAC CCC A-3'; the reverse primer had the sequence: 5'-GCC TCC ACC CCC ACC CTG TC-3') (Sigma Genosys, The Woodlands, TX 77380, USA), 1.5 mM Mg²⁺ and two units of Taq DNA polymerase (Sigma-Aldrich, St. Louis, MO 63103, USA)]. Identification of the *T786C* polymorphism was performed by enzymatic digestion of the fragment obtained by PCR amplification with the restriction endonuclease MspI. The *T786C* polymorphism creates a restriction site for the MspI enzyme.

3.2.1. Evaluation of arterial parameters

Brachial Augmentation Index (Aixb), Aortic Aix (AixAo), Pulse Wave Velocity (PWVAo), central systolic pressure and aortic Pulse Pressure (PP) was performed with the TensioMed™ Arteriograph (Budapest, Hungary).

3.3. Statistics

Data were statistically processed using the statistical package SPSS 19.0 (IBM Corporation, Armonk, NY, USA) and Medcalc 10.3.0.0 version (MedCalc Software, Ostend, Belgium). The results are presented as mean \pm standard deviation for quantitative variables with normal distribution (Kolmogorov test was used for testing the normality of data). Qualitative variables were presented as number (%). The difference between quantitative variables was assessed using the independent-sample *t*-test or Mann-Whitney test, and for qualitative variables, the χ^2 -test was used.

Data were presented as odds ratios and 95% confidence intervals. The sensitivity, specificity, positive and negative predictive values, positive likelihood ratio and negative likelihood ratio of a certain mutation/allele in the development of metabolic syndrome were calculated. Univariate analysis and logistic regression was used to identify independent predictive factors for metabolic syndrome. A *p*-value < 0.05 was considered statistically significant.

4. RESULTS

The mean age of the patients included in the study was 56.91 ± 14.39 years, sex distribution being: 66 women and 34 men. There was no significant sex difference regarding the prevalence of MS (53% in women vs. 58.8% in men, *p*-NS).

Regarding *T786C* polymorphism, the distribution of the 100 subjects was the following: 13% were homozygous (CC), 30% were heterozygous (CT), and 57% of the subjects did not have the mutation (TT). No significant sex differences was found, with the only exception being the absence of the mutation (TT) which was more frequent in the female sex (66.7% vs. 38.2%, *p*-0.011). The homozygous state (CC) was more frequent in males (20.6% vs. 9.1%, *p*-NS) compared to females, without a statistically significant difference.

The relationship between the presence of metabolic syndrome and *T786C* polymorphism is presented in Table 1. Homozygous state (CC) was more frequently met in metabolic syndrome patients (CC - 16.4% vs. 8.9%). The TT status was more frequently present in subject without metabolic syndrome (71.1% vs. 45.5% in those with MS, *p*-0.016).

The C allele was present in a proportion of 54.5% in subjects with metabolic syndrome and 28.9% in controls (*p*-0.01) – complete data are presented in Table 1.

Prevalence of hypertension and diabetes were increased in homozygous (CC) or heterozygous (CT) state vs. TT patients - 67.4% vs. 40.4%, *p*-0.0134, for hypertension and 32.6% vs. 10.5%, *p*-0.0130, for diabetes.

Table 1 | The relationship between metabolic syndrome and the *T786C* mutation

		Metabolic syndrome		Total	<i>p</i>	
		Yes	No			
<i>T786C</i> mutation	CC	No (%)	9 (16.4)	4 (8.9)	13 (13)	NS
	CT	No (%)	21 (38.2)	9 (20)	30 (30)	0.079
	CC or CT	No (%)	30 (54.6)	13 (28.9)	43 (43)	0.01
	TT	No (%)	25 (45.5)	32 (70.45)	57 (57)	0.021

p between MS patients vs. those without MS, *p* < 0.05 was considered significantly statistic.

The presence of *T786C* gene polymorphism in homozygous (CC) or heterozygous (CT) state was found to be associated with an elevation of glycemia, total cholesterol, LDL-cholesterol, serum triglycerides and a decrease of HDL-cholesterol, with an increased abdominal circumference, but without reaching statistical significance (Table 2).

The eNOS *T786C* gene polymorphism was significantly associated with the presence of metabolic syndrome, subjects having homozygous state had higher risk of having MS compared to those without the polymorphism, OR - 2.790 (95% CI 0.76–10.13, $p < 0.1$).

Sensitivity, specificity, positive predictive value, negative predictive value, +LR, -LR of allele presence (CC vs. TT) were calculated (taking into consideration as gold standard for diagnostic IDF criteria for metabolic syndrome definition).

The presence of the C allele was significantly associated with the presence of metabolic syndrome, OR - 2.86 (95% CI 1.2–6.6, $p < 0.014$). All data are presented in Tables 1 and 3.

By univariate analysis, we investigated the role of the presence of *T786C* polymorphism in the development of metabolic syndrome. In univariate analysis, increased abdominal circumference, age, weight, elevated glycemia, serum triglycerides, HDL-cholesterol and PWVAo, represent risk factors for the development of MS. The presence of the C allele of the *T786C* mutation was a risk factor for the development of metabolic syndrome (being significantly more frequently present in metabolic syndrome patients 54.5% vs. 28.9%,

Table 2 The relationship between the *T786C* mutation and biochemical parameters

	Mutation	Mean	Std. dev.	Std. error mean	<i>p</i>
Abdominal circumference (cm)	CC/CT	99.32	14.47	2.20	0.07
	TT	93.34	16.37	2.41	
Glycemia (mg/dl)	CC/CT	105.06	28.64	4.36	NS
	TT	97.76	28.07	4.09	
Total cholesterol (mg/dl)	CC/CT	201.39	62.61	9.54	NS
	TT	196.32	50.88	7.76	
LDL-cholesterol (mg/dl)	CC/CT	127.60	49.10	7.96	NS
	TT	119.67	41.14	7.38	
HDL-cholesterol (mg/dl)	CC/CT	41.02	12.62	2.04	NS
	TT	45.00	12.35	2.21	
Triglycerides (mg/dl)	CC/CT	158.11	82.27	12.54	NS
	TT	135.26	69.28	10.69	

Table 3 Indicators of the risk of *T786C* mutation in homozygous state (CC) compared to the absence of the mutation (TT)

Quantities derived from the two-by-two contingency table	Value	95% Confidence interval	
Odds ratio (OR)	2.790	0.767	10.138
Sensitivity = $a/c1 - \%$	26.47	12.91	44.36
Specificity = $d/c2 - \%$	88.57	73.24	96.7
Positive predictive value (PPV) = $a/r1 - \%$	69.2	38.61	90.72
Negative predictive value (NPV) = $d/r2 - \%$	55.3	41.47	68.65
Positive likelihood ratio (+LR)	2.32	0.79	6.81
Negative likelihood ratio (-LR)	0.83	0.66	1.070

Table 4 Coefficients and standard errors – logistic regression

	Coefficient	Std. error	<i>p</i>
Glycemia	0.122	0.038	0.0014
HDL-cholesterol	-0.207	0.065	0.0016

$p < 0.01$). The homozygous state (CC) of *T786C* polymorphism did not represent a risk factor for MS.

Using logistic regression, from previous studied factors, backward method (enter variable if $p < 0.05$, remove variable if $p > 0.1$), the independent risk factors for MS were glycemia and HDL-cholesterol. Instead, age, abdominal circumference, weight, triglycerides, PWVAo and C allele were no independent factors, were not included in the model. All data are presented in Table 4.

Regarding *T786C* polymorphism, significant differences of PWV were found between TT vs. CT vs. CC patients: 9.75 ± 1.75 m/s vs. 9.86 ± 1.56 m/s vs. 11.65 ± 1.87 m/s ($p < 0.005$) (Table 5).

For the rest of the parameters, only an ascending trend (without statistical significance) was found (AixAo, $p = 0.35$; Aixb, $p < 0.22$; PP, $p = 0.14$), with higher values being registered in CC patients.

5. DISCUSSION

The presence of the eNOS *T786C* polymorphism in homozygous or heterozygous state was associated with an increase in the prevalence of arterial hypertension (AHT) and diabetes. Like in this study, Fernandez showed that the *T786C* genotype was significantly more frequent in hypertensive patients with metabolic syndrome compared to those without metabolic syndrome ($p < 0.0022$), and concluded that the eNOS gene plays an important role in the pathogenesis of metabolic syndrome in hypertensive subjects [14].

González-Sánchez et al. [15] reported that the CC genotype was significantly more frequent in subjects with metabolic syndrome compared to those without metabolic syndrome (16.4% vs. 12.5%, $p < 0.010$) and in subjects with low HDL cholesterol (16.1% vs. 12.7%, $p < 0.044$). These data are in agreement with the data obtained in the current study.

The present study, the *T786C* gene polymorphism was significantly associated with the presence of MS. The eNOS *C786T* gene polymorphism was associated with the presence of metabolic syndrome in hypertensive subjects [14] and the eNOS haplotype, not the G894T polymorphism, was associated with the features of metabolic syndrome.

This inconsistency between studies regarding the association between the eNOS gene polymorphism and metabolic syndrome might be explained by genetic heterogeneity and by the difference between environmental factors that influence the phenotypic expression of the mutation [15]. Imamura et al. [16] demonstrated in a study that the *C-786T* allele is associated with increased blood pressure, which is significantly higher compared to subjects without the mutation. Previous studies provide clear evidence of an important physiological role of NO in the modulation of large artery properties [17–19].

Arterial stiffness varies in different arterial districts. In central arteries (such as the aorta) it is strongly influenced by age, elastin and collagen content. However, the tone of vascular smooth muscle through NO, influences the stiffness of the medium-sized muscular arteries.

Table 5 Arterial parameters depending on the *T786C* mutation

Arterial parameters	<i>T786C</i> mutation	Mean	Std. dev.	Std. error	95% CI for mean		Min. values	Max. values	<i>p</i>
					Lower	Upper			
PWVAo	TT	9.75	1.75	0.30	9.13	10.38	5.80	14.10	0.005
	CT	9.86	1.56	0.32	9.19	10.54	7.70	13.10	
	CC	11.65	1.87	0.54	10.46	12.84	8.80	14.60	
Aixb	TT	-2.07	31.96	5.48	-13.23	9.07	-59.60	52.50	0.22
	CT	1.30	26.85	5.48	-10.03	12.63	-68.30	54.60	
	CC	15.68	31.33	9.04	-4.22	35.59	-47.90	55.60	
AixAo	TT	34.46	18.11	3.06	28.24	40.68	0.00	64.20	0.35
	CT	37.97	17.24	3.52	30.69	45.26	0.00	72.10	
	CC	42.71	15.24	4.40	33.03	52.40	13.40	65.80	
PP	TT	53.37	12.81	2.16	48.96	57.77	36.00	80.00	0.14
	CT	51.33	11.76	2.40	46.36	56.30	35.00	77.00	
	CC	60.91	19.42	5.60	48.57	73.25	39.00	100.00	

p between registered values in TT patients vs. CT patients vs. CC patients (*p* was calculated using ANOVA test).

Endothelium-derived NO (synthesized from L-arginine by eNOS [20–22] has multiple physiological properties, modulating growth and migration of vascular smooth muscle cells and relaxing vascular smooth muscle [20,23]. Genetic factors, determining eNOS abnormalities, reduce bioavailability of NO [21,23].

In previous studies on mice, NOS3 knockout was associated with elevation in pulse pressure [21]. NOS3 has a role in the modulation of arterial properties, an association between NOS3 gene polymorphism and arterial function being found. In several studies, eNOS gene polymorphisms have been associated with arterial stiffness parameters [22,24].

Using ANOVA test, we found significant differences regarding PWVAo between TT and CT and CC subjects. For Aixb, AixAo and aortic PP, homozygous (CC) patients presenting higher values, but without statistical significance. Mayer et al. [22] demonstrated in a study that the homozygous and heterozygous status of *T786C* polymorphism is accompanied by significantly higher values of pulse wave velocity compared to mutation-free subjects (14.0 vs. 10.7 m/s, $p < 0.002$); Mitchell showed that Glu298Asp polymorphism is correlated with pulse pressure and the reflected wave amplitude only in women [23]. After adjustment for multiple factors, the association between eNOS polymorphism and arterial stiffness was no longer maintained. Our group found that *G894T* polymorphism did not significantly influence the values of the arterial stiffness (PWV, Aixb and AixAo) [24]. The mutated T allele of rs3918226 polymorphism in the *NOS3* gene was associated with parameters reflecting central arterial stiffness and wave reflection [25].

In women but not men, the genotype for the common *NOS3* missense mutation (Glu298Asp, rs1799983) was related to central pulse pressure and forward wave amplitude [23]. In the current study, in univariate analysis, age, weight, increased abdominal circumference, elevated levels of glycemia and serum triglycerides, low HDL-cholesterol and high PWVAo represented risk factors for the development of metabolic syndrome.

The presence of the C allele of the *T786C* mutation was a risk factor for the development of metabolic syndrome.

6. CONCLUSION

The eNOS *T786C* gene polymorphism in homozygous and heterozygous state was significantly associated with the presence of metabolic syndrome and with an increase in the prevalence of AHT and diabetes mellitus.

The *T786C* polymorphism influences arterial stiffness parameters, specifically PWV, which is the gold standard for arterial stiffness. Arterial stiffness is influenced by eNOS *T786C* gene polymorphisms, being a possible link between the increase cardiovascular risk and presence of metabolic syndrome in these patients.

CONFLICTS OF INTEREST

The authors declare they have no conflicts of interest.

AUTHORS' CONTRIBUTION

AC, AV and ST contributed in concept and design of the study, data acquisition, analysis and interpretation of data, drafting and revising the article for intellectual content. OHO contributed in concept and design of the study, analysis and interpretation of data, drafting and revising the article for intellectual content. AF contributed in data acquisition, analysis and interpretation of data, drafting and revising the article. TA and VN contributed in analysis and interpretation of data, revising the article for intellectual content. LMP contributed in genetic analysis and interpretation of data, drafting and revising the article. DP and DAT contributed in concept and design of the study, revising the article for intellectual content. All authors read and approved the final manuscript.

FUNDING

No financial support was provided.

REFERENCES

- [1] Vecoli C. Endothelial nitric oxide synthase gene polymorphisms in cardiovascular disease. *Vitam Horm* 2014;96:387–406.
- [2] Zeng WP, Zhang R, Li R, Luo JF, Hu XF. Association of the endothelial nitric oxide synthase gene T786C polymorphism with in-stent restenosis in Chinese Han patients with coronary artery disease treated with drug-eluting stent. *PloS One* 2017;12:e0170964.
- [3] Xie X, Shi X, Xun X, Rao L. Endothelial nitric oxide synthase gene single nucleotide polymorphisms and the risk of hypertension: a meta-analysis involving 63,258 subjects. *Clin Exp Hypertens* 2017;39:175–82.
- [4] Konsola T, Siasos G, Antonopoulos AS, Kollia C, Oikonomou E, Tentolouris N, et al. The impact of T786C and G894T polymorphisms of eNOS on vascular endothelial growth factor serum levels in type 2 diabetes patients. *Int J Cardiol* 2016;222:155–6.
- [5] Ma Q, Lv J, Huang K, Guo H, Yang W, Luo W, et al. Endothelial nitric oxide synthase gene G894T polymorphism and risk assessment for pregnancy-induced hypertension: evidence from 11 700 subjects. *Hypertens Res* 2016;39:899–906.
- [6] Alrefai AA, El-din Habib MS, Yaseen RI, Gabr MK, Habeeb RM. Association of endothelial nitric oxide synthase (eNOS) gene G894T polymorphism with hypertension risk and complications. *Mol Cell Biochem* 2016;421:103–10.
- [7] Yang C, Qi ZY, Shao C, Xing WK, Wang Z. Association between three eNOS polymorphisms and intracranial aneurysms risk: a meta-analysis. *Medicine (Baltimore)* 2015;94:e452.
- [8] Guo X. Endothelial nitric oxide (eNOS) gene G894T and VNTR polymorphisms are closely associated with the risk of ischemic stroke development for Asians: meta-analysis of epidemiological studies. *Mol Biol Rep* 2014;41:2571–83.
- [9] Kumar A, Misra S, Kumar P, Prasad K, Pandit AK, Chakravarty K, et al. Association between endothelial nitric oxide synthase gene polymorphisms and risk of ischemic stroke: a meta-analysis. *Neurol India* 2017;65:22–34.
- [10] Shyu HY, Chen MH, Hsieh YH, Shieh JC, Yen LR, Wang HW, et al. Association of eNOS and Cav-1 gene polymorphisms with susceptibility risk of large artery atherosclerotic stroke. *PloS One* 2017;12:e0174110.
- [11] Fodor A, Cozma A, Karnieli E. Personalized epigenetic management of diabetes. *Per Med* 2015;12:497–514.
- [12] Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. *Hypertension* 2004;43:1239–45.
- [13] Gkaliagkousi E, Ferro A. Nitric oxide signalling in the regulation of cardiovascular and platelet function. *Front Biosci (Landmark Ed)* 2011;16:1873–97.
- [14] Fernandez ML, Ruiz R, Gonzalez MA, Ramirez-Lorca R, Couto C, Ramos A, et al. Association of NOS3 gene with metabolic syndrome in hypertensive patients. *Thromb Haemost* 2004;92:413–8.
- [15] González-Sánchez JL, Martínez-Larrad MT, Sáez ME, Zabena C, Martínez-Calatrava MJ, Serrano-Ríos M. Endothelial nitric oxide synthase haplotypes are associated with features of metabolic syndrome. *Clin Chem* 2007;53:91–7.
- [16] Imamura A, Takahashi R, Murakami R, Kataoka H, Cheng XW, Numaguchi Y, et al. The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels. *Eur J Endocrinol* 2008;158:189–95.
- [17] Fitch RM, Vergona R, Sullivan ME, Wang YX. Nitric oxide synthase inhibition increases aortic stiffness measured by pulse wave velocity in rats. *Cardiovasc Res* 2001;51:351–8.
- [18] Kinlay S, Creager MA, Fukumoto M, Hikita H, Fang JC, Selwyn AP, et al. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. *Hypertension* 2001;38:1049–53.
- [19] Ramsey MW, Goodfellow J, Jones CJH, Luddington LA, Lewis MJ, Henderson AH. Endothelial control of arterial distensibility is impaired in chronic heart failure. *Circulation* 1995;92:3212–9.
- [20] Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. *Prog Cardiovasc Dis* 1995;38:87–104.
- [21] Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol Rev* 1991;43:109–42.
- [22] Mayer O, Filipovský J, Pesta M, Cífková R, Dolejšová M, Simon J. The interaction of endothelial nitric oxide synthase polymorphism and current smoking in terms of increased arterial stiffness. *Physiol Res* 2010;59:529–36.
- [23] Mitchell GF, Guo CY, Kathiresan S, Vasani RS, Larson MG, Vita JA, et al. Vascular stiffness and genetic variation at the endothelial nitric oxide synthase locus: the Framingham Heart study. *Hypertension* 2007;49:1285–90.
- [24] Cozma A, Sitar-Taut A, Orasan O, Procopciuc LM, Farcas AD, Stan A, et al. The relationship between eNOS (G894T) gene polymorphism and arterial stiffness in patients with metabolic syndrome. *Rev Chim* 2018;69:2351–6.
- [25] Seidlerová J, Filipovský J, Mayer O, Kučerová A, Pešta M. Association between endothelial NO synthase polymorphisms and arterial properties in the general population. *Nitric Oxide* 2015;44:47–51.